Opinion|Videos|February 17, 2025
Locally Advanced HER2+ Breast Cancer
Panelists discuss how, locally advanced HER2-positive breast cancer is characterized by overexpression of HER2 proteins with regional spread beyond the primary tumor, involving either extensive lymph node involvement, chest wall, or skin, but without distant metastases. Treatment typically combines targeted HER2 therapy, chemotherapy, and local interventions.
Advertisement
Advertisement
Related to this article
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
3
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5